A new *Borrelia* on the block: *Borrelia miyamotoi* – a human health risk?

Sally Cutler¹, Muriel Vayssier-Taussat², Agustín Estrada-Peña³, Aleksandar Potkonjak⁴, Andrei Daniel Mihalca⁵, Hervé Zeller⁶

1. School of Health, Sport & Bioscience, University of East London, London, United Kingdom

2. INRA, UMR BIPAR INRA, ENVA, Anses, Maisons-Alfort, France

3. Department of Animal Health, Faculty of Veterinary Medicine, University of Zaragoza, Spain

4. Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad, Serbia

5. Department of Parasitology and Parasitic Diseases, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, Romania

6. European Centre for Disease Prevention and Control, Solna, Sweden

Correspondence: Sally J. Cutler (s.cutler@uel.ac.uk)

Citation style for this article:

Cutler Sally, Vayssier-Taussat Muriel, Estrada-Peña Agustín, Potkonjak Aleksandar, Mihalca Andrei Daniel, Zeller Hervé. A new *Borrelia* on the block: *Borrelia miyamotoi* – a human health risk?. *Euro Surveill.* 2019;24(18):pii=1800170. <https://doi.org/10.2807/1560-7917.ES.2019.24.18.1800170>

Article submitted on 04 Apr 2018 / accepted on 11 Mar 2019 / published on 02 May 2019

Background: *Borrelia miyamotoi* clusters phylogenetically among relapsing fever borreliae, but is transmitted by hard ticks. Recent recognition as a human pathogen has intensified research into its ecology and pathogenic potential. **Aims:** We aimed to provide a timely critical integrative evaluation of our knowledge on *B. miyamotoi*, to assess its public health relevance and guide future research. **Methods:** This narrative review used peer-reviewed literature in English from January 1994 to December 2018. **Results:** *Borrelia miyamotoi* occurs in the world's northern hemisphere where it co-circulates with *B. burgdorferi sensu lato*, which causes Lyme disease. The two borreliae have overlapping vertebrate and tick hosts. While ticks serve as vectors for both species, they are also reservoirs for *B. miyamotoi*. Three *B. miyamotoi* genotypes are described, but further diversity is being recognised. The lack of sufficient cultivable isolates and vertebrate models compromise investigation of human infection and its consequences. Our understanding mainly originates from limited case series. In these, human infections mostly present as influenza-like illness, with relapsing fever in sporadic cases and neurological disease reported in immunocompromised patients. Unspecific clinical presentation, also occasionally resulting from Lyme- or other co-infections, complicates diagnosis, likely contributing to under-reporting. Diagnostics mainly employ PCR and serology. *Borrelia miyamotoi* infections are treated with antimicrobials according to regimes used for Lyme disease. **Conclusions:** With co-infection of tick-borne pathogens being commonplace, diagnostic improvements remain important. Developing in vivo models might allow more insight into human pathogenesis. Continued ecological and human case studies are key to better epidemiological understanding, guiding intervention strategies.

Introduction

Borrelia miyamotoi, which belongs to the relapsing fever clade within the *Borrelia* genus, was first described in 1994 with its detection in *Ixodes persulcatus* ticks in Japan [1]. It was named after Professor Kenji Miyamoto who initially reported this spirochaete from Hokkaido, Japan. Its potential to cause human disease was not realised until 2011 when Platonov and colleagues described a series of cases of *B. miyamotoi* infection in Russia [2].

It is now established that this spirochaete has a global distribution and co-circulates with the related agent of Lyme borreliosis (Lyme disease), *B. burgdorferi sensu lato* (s.l.), which uses the same tick species as vectors, albeit at a lower frequency [3-9]. Similar to the Lyme borreliae, where different tick species endemic to specific regions of the globe serve as vectors, *B. miyamotoi* is found in multiple tick species that reside constrained by compatible geo-ecological habitats [2-4,10-13].

The objectives of this review were threefold: (i) to collate the rapid expansion of research findings on *B. miyamotoi* and its ecological interactions; (ii) to review the public health significance of *B. miyamotoi* and to (iii) highlight knowledge gaps in our understanding of this microbe and its importance as a human pathogen, thus focussing direction for future research.

Methods

We performed a non-systematic narrative literature review. Literature searches were thus not fully exhaustive. Reports relating to the search term '*Borrelia miyamotoi*' published in English and indexed in biomedical databases including EBSCO (Academic Search Complete), Scopus and Science Direct were sought

(Figure 1). These dated from the first description of *B. miyamotoi* in January 1994 to December 2018. Duplicate records were removed and articles were further screened, first by reading the titles and abstracts, then the full reports. Prioritisation to those papers that contributed original knowledge to our understanding was given. Supplementary literature was used to further support discussions beyond primary searches where justifiable (Figure 1).

Results

Epidemiology

Borrelia miyamotoi is being increasingly documented from the world's northern hemisphere. This spirochaete has been recorded in Canada as well on the east and west coasts of the United States (US). It has also been observed in numerous European countries (including the Czech Republic, Denmark, Estonia, France, Germany, Netherlands, Norway, Poland, Romania, Sweden and Switzerland) as well as in Russia through to Japan [3,10,14,15].

Surveys to detect *B. miyamotoi* have tended to reflect local research interest rather than being systematic epidemiological studies. These have however established that endemic areas for *B. miyamotoi* overlap with those for Lyme borreliosis (*B. burgdorferi* s.l.), and during tick surveys, specimens co-infected with both spirochaetes have been identified [4,11,16]. In several countries, prevalence studies based upon individual ticks infected with borreliosis have noted lower rates of ticks infected with *B. miyamotoi* than with Lyme-associated borreliosis [5,17].

Among 20 studies found in this review, from countries reporting clinical cases and *B. miyamotoi* prevalence in ticks, infection rates in ticks ranged from 0.02 to 6.4%, although most studies reported a range between 1 and 2% (Table 1) [3,5,15,18,19]. Nevertheless, pockets of higher infection rates have been described. In Napa County, California, US, for example, 15.4% of adult ticks (10/65 *I. pacificus*) studied were infected with *B. miyamotoi* [3] compared with a background infection level of 1.4% (44/3,255) of nymphs of this same species [19]. Moreover, in a study in Kurgan, Russia, 16% of ticks (26/162 *I. persulcatus*) were found infected [2]. These rates might reflect either hyperendemic areas or local efficient transmission events.

In some countries, such as Mongolia, where relatively high levels of tick infections with *B. miyamotoi* (4.5%; 48/1,069 *I. persulcatus*) have been detected, no human cases were reported [10]. This was similar in the town of Hannover, Germany, where a tick-infection prevalence of 8.9% (45/505 *I. ricinus* ticks) was reported but no infections in people [20]. On the other hand, on Hokkaido Island, Japan, where, depending on the tick species, 2% (71/3,532 *I. persulcatus*) and 4.3% (5/117 *I. pavlovskyi*) of ticks were infected, human cases did occur [4]. Human cases were also observed in the

Irkutsk region, Russia, where an overall 2.9% prevalence of tick infection has been estimated [21] (Table 1). In Yekaterinburg and Izhevsk, where clinical cases were first described, tick (*I. persulcatus*) infection prevalence rates of 0.9% (4/442) and 6.3% (25/394) were respectively found. Estimated incidence of human infection with *B. miyamotoi* in Yekaterinburg is likely to be 1 per 100,000 per year, accounting for a quarter of tick-borne borreliosis cases within this province [2,22].

Phylogeny and diversity of *Borrelia miyamotoi*

The taxonomic definition of the genus *Borrelia* is currently debated with the suggestion that the Lyme disease associated members be removed from this genus, and instead be placed in a new genus, *Borrelia* [23]. This suggestion has not been met with universal approval, with some experts suggesting this division is premature given the current discovery of new spirochaetes [24,25]. *Borrelia miyamotoi* clusters among the relapsing fever spirochaetes, but unlike these, resides alongside *B. theileri* and *B. lonestari* that are also transmitted by hard ticks (Figure 2). Until recently, it was believed that *B. miyamotoi* fell into three geographically separated clades (genotypes), namely the Asian (or Siberian), European and American, (Figure 2, Table 2), transmitted by *I. persulcatus*/*I. pavlovskyi* (*I. ovatus*), *I. ricinus* and *I. scapularis* or *I. pacificus*, respectively [26,27].

However, as knowledge of this particular spirochaete increases, more diversity within the species is being recognised. A slight sequence variation was observed among the Asian clade based upon 16S sequence data, typified by strain Y14T1 from *I. persulcatus* ticks (Figure 2) that revealed sequence divergence from other members within this clade [10]. Similarly, in the US, divergence was noted among sequence types of American *B. miyamotoi* associated with *I. pacificus* (Figure 2) [12,28]. Given the highly conserved nature of 16S, it is not generally considered a reliable marker for the delineation of borreliosis [29], as such, the level of heterogeneity among these variants might be considerably more than that inferred from 16S data alone.

A potential fourth clade was recently described for strains found in *I. ovatus* ticks in Japan. These showed clear separation from the established sequence types for 16S rRNA (Figure 2) and the clade was further confirmed using more discriminatory multilocus sequence typing (MLST) phylogenetic approaches [30]. Representatives of this potentially novel clade of *B. miyamotoi* were carried by up to 0.6% of ticks collected from Honshu Island, but were absent from those ticks collected in Hokkaido, Japan [4,10].

Strains belonging to different genotypes of *B. miyamotoi* have been observed to geographically overlap. Asian and European genotypes have been detected in Russia and Estonia [2,11]. In south-eastern Estonia, the Asian strains were detected in both *I. persulcatus* and *I.*

FIGURE 1

Flow chart of the search strategy and inclusion of identified articles, narrative literature review of *Borrelia miyamotoi*

Literature used was derived from sifting EBSCO, Science Direct and Scopus databases searching for ‘*Borrelia miyamotoi*’ from January 1994 through to December 2018.

^a Additional supplementary information was included as indicated to support discussion points as required. This included information on the pathobiology of other relapsing fever species.

ricinus while the European strains could only be found in *I. ricinus* [11].

The situation in Estonia also illustrates that a single tick species (e.g. *I. ricinus*) can harbour several genotypes [11], a phenomenon that has also been observed for *I. ovatus*, which can be infected by both the Asian and the new variant genotype [10]. On the other hand, some genotypes have been found in multiple tick species such as the American strain found in *I. scapularis* and *I. dentatus* [31], with its close variant present in *I. pacificus* [12]. Furthermore, there are reports of Asian clade representatives of *B. miyamotoi* in other types of ticks such as *Haemaphysalis concinna* [13] and *H. longicornis* [32], but the ecological role of these species for maintaining this spirochaete has not been fully elucidated. Thus vector specificity may not be as strict as previous data suggested.

Ecology

In studies assessing single strains of *B. miyamotoi* and their associated tick species, the spirochaete has been detected among unfed larval ticks, suggesting successful transovarial (i.e. vertical) transmission to successive generations of ticks. Thus, ticks should be considered as both vectors and reservoirs for *B. miyamotoi*. Vertical transmission is estimated to have a frequency of less than 0.8 per tick generation, thus not sufficient to sustain *B. miyamotoi* for more than a few successive generations, in isolation of other transmission mechanisms [6,33]. That such mechanisms are needed has gained further support from laboratory-based *in vivo* infection studies suggesting a decline of tick infection by *B. miyamotoi* during their development, through trans-stadial moults [34]. Prevalence studies conducted with different *B. miyamotoi* tick instars revealed lower infection rates among larvae than among nymphal and adult ticks (which had equivalent rates) [35]. The higher infection rates in nymphs and adults possibly result from infection of ticks by feeding (i.e. horizontal transmission) later in their life cycle. This contrasts with a staged infection rate by instar reported for *B. burgdorferi* s.l. [11,17], whereby infection may occur predominantly by horizontal transmission (i.e. feeding).

Similar to other borreliae, prevalence of *B. miyamotoi* appears to be amplified through infection of certain avian and rodent species. Varied small vertebrate species have been shown to be competent reservoirs of infection by *B. miyamotoi* including mice (*Apodemus* spp. and *Peromyscus* spp.), voles (*Microtus* spp., *Myodes glareolus*, and *Microtus arvalis*), chipmunks (*Tamias* sp.), squirrels (*Sciuridae* spp.), European hedgehogs (*Erinaceus europaeus*) and racoons (*Procyon* spp.) [6-8,15,31,36-39]. Avian species have not been extensively surveyed, but *B. miyamotoi* has been detected in blackbirds (*Turdus merula*), great tits (*Parus major*), common chiffchaff (*Phylloscopus collybita*), song thrush (*Turdus philomelos*), European robin (*Erithacus rubecula*) and European greenfinch (*Chloris chloris*) albeit at low levels 0.6–8% of avian-removed ticks [15,31,40]. A report from Tennessee, US describes a surprisingly high level of *B. miyamotoi* infection among wild turkeys (*Meleagris gallopavo*) with 58% (35/60) birds sampled testing positive for *B. miyamotoi* [41]. These birds were heavily infested with *A. americanum* ticks (70%; 42/60), but none of the ticks were positive for *B. miyamotoi* [41].

Furthermore, larger vertebrates have been found with evidence of infection such as wild boar [42,43] but their ecological significance remains unclear. Interestingly, deer have been suggested to amplify *B. miyamotoi* tick infection rates in the US [44] and representatives of the Asian genotype of *B. miyamotoi* have been recovered from infected deer in the far East [32]. These observations contrast with the Lyme borreliae, where deer are not competent species to enhance transmission to ticks during feeding. Nevertheless, it must be noted

that a study from Japan failed to demonstrate *B. miyamotoi* in deer, but instead reported another hard-tick vectored borrelial species resembling *B. theileri* and *B. lonestari* [45] that had been previously reported from Japanese *Haemaphysalis* spp. ticks [46] and *H. longicornis* from China [32]. A role for deer was also not corroborated by a study from the Netherlands and the European genotype [15]. Because the various studies reported here were based upon different *B. miyamotoi* genotypes, strain differences might explain the differences observed for transmission efficiency following ticks feeding upon deer.

Relations between *Borrelia miyamotoi* and *Borrelia burgdorferi* s.l.

In vertebrates, co-infection with *B. miyamotoi* and *B. burgdorferi* has been recorded, but the probability of dual infection appears no greater than that which would be expected independently by chance [6].

In ticks however, it remains a question whether co-infection happens at random or not. Some studies suggest that co-infection is more frequent than either infection alone [15]. Others however suggest that this happens by chance. For example, subsequent to a study finding 264/5,431 (4.9%) *B. burgdorferi* sensu stricto in nymphal *I. pacificus* ticks, a subset of 3,255 ticks was retested for *B. miyamotoi*. A total of 44 (1.4%) ticks were infected *B. miyamotoi* alone, and only one single individual with *B. burgdorferi* sensu stricto was also found co-infected with *B. miyamotoi* [19,47]. On the other hand, among *I. scapularis* ticks from Midwestern US, Hamer et al. report a 2.1 times lower level of co-infection with *B. burgdorferi* and *B. miyamotoi* (0.05% co-infection among 1,565 questing adult ticks) than expected by chance [48].

Tick surveillance demonstrates that *B. burgdorferi* s.l. is more prevalent than *B. miyamotoi*, approximating to a ratio of 10:1 or greater in several studies [5,6,48,49]. This is intriguing given that an American study suggests that both species infect ticks to equivalent levels achieving infection rates of around 2,000 spirochaetes for nymphs and 5,000 for adult ticks (sometimes higher in the case of *B. miyamotoi*) [6]. A European study, which quantified by PCR *B. miyamotoi* in feeding ticks removed from humans, even reported considerably higher borrelial tick loads by *B. miyamotoi* (mean count of 2.1×10^5) than by *B. burgdorferi* s.l. (with a mean of 4.5×10^3 for *B. afzelii* and 2.7×10^3 for *B. garinii*) [49]. Thus, infection prevalence among ticks is higher for *B. burgdorferi* s.l. [5,6,48,49], however, *B. miyamotoi*-infected ticks appear to have equivalent [6], or higher quantities of borreliae within their tissues [49].

The answer to why we observe higher prevalence for *B. burgdorferi* s.l. compared with *B. miyamotoi* in ticks, might reside in the superior ability for *B. burgdorferi* to persist in the skin of its vertebrate host, potentially extending the window of transmission to other feeding ticks. The failure to detect *B. miyamotoi* in the skin of

erythema migrans patients corroborates this theory [15]. Moreover, studies of *Peromyscus leucopus* mice during *I. scapularis* nymphal questing times have shown that Lyme-associated borreliae resided in the skin of their host, while *B. miyamotoi* gave a higher blood burden with density counts five times higher than *B. burgdorferi* s.l. [6]. While levels up to 251 spirochaetes of *B. miyamotoi* per mL blood have been observed, persistence in blood within an infected vertebrate appears comparable to *B. burgdorferi* s.l. [6,50].

The sympatric overlap of *B. burgdorferi* s.l. and *B. miyamotoi* begs the question as to how these closely related spirochaetes might interact. Remarkably, the prevalence of *B. miyamotoi* infection in ticks appears indifferent to variations in the habitat type, or to ecological influences that impact upon the prevalence of *B. burgdorferi* s.l. [19]. As nutritional requirements are likely to overlap, is there antagonism between these species, indifference or a more synergistic relationship? Competitive interactions have not been explored per se, however, emerging data suggest that these species appear indifferent to each other. A study of shared small rodent hosts suggests different seasonal peaks of infection, with *B. burgdorferi* s.l. rodent infection peaking in spring and being driven by nymphs, whereas *B. miyamotoi* rodent infection being predominant in summertime through larval ticks [51,52]. This separation might provide a means for both spirochaetes to co-exist [6]. Indeed, transovarial tick transmission of *B. miyamotoi* enables larval ticks to be infectious for their subsequent hosts. In contrast, tick larvae harbouring *B. burgdorferi* s.l. are rarely reported, suggesting infrequent vertical transmission in *B. burgdorferi* s.l. Among field-collected larvae, a study found *B. burgdorferi* s.l. in 0.62% as opposed to 2% for *B. miyamotoi* [53]. Some recent publications query whether previously reported low levels of *B. burgdorferi* s.l. vertical transmission constituted in fact detection of *B. miyamotoi* [54,55].

Transmission to humans, magnitude of human infection and pathogenesis

Emerging evidence supports presence of *B. miyamotoi* in tick salivary glands [34], with a study finding that over 88% of second generation progeny of infected *I. scapularis* nymphal ticks had *B. miyamotoi* in their salivary glands, as seen with other relapsing fever spirochaetes in their soft tick vectors [56]. Experimental mouse (CD-1 outbred *Mus musculus* mice) transmission studies using ticks derived from a field collected population infected with the American strain of *B. miyamotoi*, have demonstrated 10% infection after 24hrs, rising to 31% at 48hrs and 63% by 72hrs [56]. Though not as rapid as the transmission of classical relapsing fever spirochaetes by their soft tick vectors [57], this demonstrates transmission of *B. miyamotoi* in the first day of tick attachment, contrasting with the days of attachment needed by Lyme borreliae to migrate from the tick midgut to salivary glands for transmission [57].

TABLE 1

Studies worldwide reporting *Borrelia miyamotoi* infections, with diagnostic methods, prevalence and human clinical signs, 1994–2018

Location	<i>Borrelia miyamotoi</i> cases with reference (year of publication)	Percentage of cases among persons studied	Reported infection prevalence in ticks	Clinical signs	Diagnostic method	References for prevalence in ticks and human cases
Russia	51/302 humans bitten by ticks (2011) [2]	16.9%	<i>Ixodes ricinus</i> 0.8% <i>I. persulcatus</i> 2.9–10.5% <i>I. pavlovski</i> 6.4%	Fever, chills, sweating, headache, fatigue and vomiting (relapsing fever in 5)	PCR and serology	[2,21,104,105]
Izhevsk, Russia	2/24 <i>B. miyamotoi</i> infected-tick bites developed disease (2015) [58]	8.3%		Fever, chills, sweating, headache, fatigue, nausea, vomiting, dizziness.	PCR and serology	[58]
Yekaterinburg, Russia	71/459 tick-borne infection (including 1 ^a also with Lyme borreliosis) (2018) [22]	15.5%		Clinical details not described.	PCR and serology	[2,22]
China	14/984 patients with tick-borne infection (2018) [13]	1.4%	<i>I. persulcatus</i> 53% <i>Hyalomma concinna</i> 2.8%	Fever, headache, anorexia, asthenia, arthralgia	PCR	[13]
Hokkaido, Japan	2 ^a /408 Lyme borreliosis cases (2014) [75]	0.49%	<i>I. persulcatus</i> 1.6–2% <i>I. pavlovski</i> 4.3% <i>I. ovatus</i> 0.5%	Fever, myalgia, anorexia	PCR and serology	[4,10,75]
Japan	12/459 suspected Lyme borreliosis (2018) [64]	2.6%		One case meningoencephalitis; clinical history not disclosed on remainder.	Serology	[4,10,64]
Hokkaido, Japan	1 case study (2017) [80]	NA		Fever, macular erythematous rash, low blood pressure, thrombocytopenia.	Serology	[4,10,80]
Germany	1 case study suspected Lyme neuroborreliosis (2016) [72]	NA	<i>I. ricinus</i> 1.2–2.4%	Lymphomatous meningitis (immunocompromised)	PCR, CXCL13 and microscopy	[3,5,72,82]
Netherlands	1 case study (2013) [73]	NA	<i>I. ricinus</i> 2.1–3.6%	Meningoencephalitis (immunocompromised)	Microscopy, PCR and equivocal serology	[15,73,106,107]
Netherlands	1 case study (2018) [103]	NA		Lymphadenopathy, leucopenia and thrombocytopenia (immunocompetent)	Serology	[15,103]
United States	97/11,515 acute febrile patients (2015) [78]	0.84%	<i>I. scapularis</i> 0.02–3.1% <i>I. pacificus</i> 0.4–2%	Fever, chills, myalgia, arthralgia, headaches, neutropenia, thrombocytopenia	PCR	[3,6,18,19,35,78,83,108]

NA: not applicable.

^a Denotes dual-infected cases who also presented with erythema migrans lesions.

In this respect, in humans, transmission efficiency has been estimated at 8.3% [58], based upon a cohort of 24 persons bitten by PCR-positive ticks, of whom only two later developed compatible clinical disease [58]. By comparison, three of 68 (4.4%), humans bitten by *B. burgdorferi* s.l. infected ticks, developed disease (erythema migrans) [58,59].

In terms of the magnitude of human infections with *B. miyamotoi*, this depends to some extent on the frequency of tick bites among people and on the

prevalence of tick infection. Ixodid ticks are holarctic in distribution and assessments of tick bites vary by country and location. In the Netherlands, it was estimated that tick bites amount to 71,980 per million inhabitants (2007) [60]. In the Irkutsk region in Russia 2014, tick bites were estimated at 12,500 per million people [21]. The prevalence of infection among ticks ranges from 0.5 to 6% in many regions of the northern hemisphere. Taken together with a transmission rate of 8.3% [58], it is likely that human infections are underestimated [61].

In Yekaterinburg Province, Russia in 2009, it was estimated *B. miyamotoi* infections occur in 1 per 100,000 inhabitants [2]. Studies from the Netherlands suggest that some 36,000 humans are bitten each year by *B. miyamotoi* (European strain) infected ticks [9]. Serological studies from the US appear to corroborate human exposure [62,63]. Despite this, reports of human infections are comparatively few; for example, retrospective serological evaluation of sera from cases suspected for Lyme disease only detected 19 indigenous cases in Japan between 2013 and 2017 [64].

Borreliae as a group, are renowned for their ability to persist within humans. Relapsing fever *Borrelia* undergo an elaborate series of antigenic variation coupled with other mechanisms such as binding factor H and evading the components of the complement cascade, enabling their persistence in blood or their human host over time. Likewise, *B. miyamotoi* possesses variable membrane proteins (vmp) that could facilitate relapse with different antigenic variants [65], and has the ability to bind factor H and related proteins, thus evading host complement-mediated degradation [66-68]. Clinical reports of relapse with *B. miyamotoi* infection are described in the literature, however surprisingly, this appears less frequently than seen with classical relapsing fever infections [2,69].

The borreliae have proven neurotropism potential, using the nervous system as an immunologically protected niche enabling persistence in their vertebrate host [70,71]. The precise mechanisms by which spirochaetes exploit this niche are poorly understood, but animal studies have shown that relapsing fever *Borrelia* can survive for 270 days within this site, thus enabling greater *in vivo* persistence [70]. Neurological sequelae have been a feature of infection among immunocompromised individuals (see clinical presentations below) [72-74]. An *in vivo* infection model is urgently needed to unravel the pathogenesis of human *B. miyamotoi* infection. A severe combined immune deficiency (SCID) mouse model has been established [34], but has limitations to extrapolate to infection in immunocompetent humans.

Clinical presentation

Clinical cases have been reported from Europe, Japan [4,64,75], China [13], Russia [2] and the US [76-78]. Infection with *B. miyamotoi* does not present with obvious hallmark signs. Instead, patients present with fever accompanied by non-specific influenza-like symptoms, such as chills, fatigue, headache, myalgia and arthralgia (Table 1) [9].

Although *B. miyamotoi* clusters within the relapsing fever group of spirochaetes, cases with the characteristic recurring febrile episodes interspersed with non-febrile intervals that typify classical relapsing fever have only been described sporadically [2,79]. In these, up to three febrile episodes have been recorded [2], however this might be an underestimation given that

patients are typically managed with antimicrobial therapy upon diagnosis. A case who was retrospectively diagnosed following spontaneous recovery had a documented relapsing illness with two episodes, albeit with a lengthy 3-week afebrile period [69].

Furthermore, unlike relapsing fever spirochaetes, epistaxis, abortion, jaundice and major organ failure have not appeared as features of *B. miyamotoi* infection. Nevertheless, both *B. miyamotoi* and classical relapsing fever share fever, headaches, chills, myalgia, arthralgia, and nausea/vomiting.

Some differences in clinical presentation have been noted between US and Russian cases, particularly regarding the presence of thrombocytopenia documented in approximately half of American cases [78], but not reported from those in Russia. This differential clinical presentation may be an artefact given the recent description of thrombocytopenia in a Japanese clinical case infected with an Asian *B. miyamotoi* strain [80], akin to those reported from Russian cases.

In two studies, cases have been reported with erythema migrans [75,78], however it is likely that these had concomitant infection with *B. burgdorferi* s.l., thus representing co-infections. Indeed, one of these studies retrospectively sought presence of *B. miyamotoi* in sera from cases diagnosed with Lyme disease, whereas the other reported one case of erythema migrans among 51 *B. miyamotoi* patients who had an overall 14% co-infection rate with *B. burgdorferi* s.l. A larger study of 71 PCR-confirmed *B. miyamotoi* infected cases from Yekaterinburg, Russia, found only five of these cases with erythema migrans [22]. Analysis of blood for confirmation of pathogens disclosed that one case was co-infected with *B. burgdorferi* s.l., but it was concluded that the remaining cases with erythema migrans were realistically also co-infections given the poor sensitivity of PCR to detect Lyme disease using blood samples (as *B. burgdorferi* s.l. tends to be found in the skin) [22,49].

Borrelia miyamotoi, like other members of the borreliae have demonstrated their ability to result in neurological sequelae with descriptions of meningoencephalitis, albeit among immunocompromised individuals [64,72-74]. Unlike the acute febrile presentation described above, infections in these immunocompromised cases described to date, have shown a more insidious onset, often over several months. One case presented with memory deficits and disturbed gait, with lumbar puncture revealing pleocytosis and raised cerebrospinal fluid (CSF) protein [73].

Diagnostics

For immunocompromised patients, diagnosis with microscopy has been used to a certain extent [72-74], sometimes combined with immunofluorescence [74]. For example, in three case reports on immunocompromised patients infected with *B. miyamotoi* [72-74],

FIGURE 2

Strain diversity of *Borrelia miyamotoi* based upon 16S rRNA sequences

European, American and Asian clusters are demonstrated alongside newly described strains, using classical relapsing fever species and other hard tick borreliae as outgroups. The colours of the branches denote the different clades and highlight variant strains. Tree labels provide GenBank accession numbers; strain reference; country of origin and source of sequence. The tree was compiled using a neighbour-joining algorithm, with clusters assessed using the bootstrap test for stringency (1,000 replicates). The percentages of replicate trees in which the associated isolates clustered together are shown next to the branches. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. These units represent the number of base substitutions per site. Evolutionary analyses were conducted in MEGA7.

spirochaetes in the CSF were retrospectively detected by microscopy in one case [73]. For the other two cases, *B. miyamotoi* was also identified by microscopy, albeit after concentration of the CSF sample and either Giemsa or acridine orange staining [72,74]. For all three cases, however, microscopy was complemented with PCR for diagnosis confirmation [72-74].

Generally, for overall patients, diagnostic approaches depend on the stage and duration of infection. During the acute phase of infection, the presence of the spirochaete in blood and CSF can be demonstrated using PCR and microscopy. The success of such methods rapidly reduces from the fourth day of disease correlated with depletion in the spirochaetal blood counts [22]. Clinical reports of relapse are described in the literature [2,69]. If this occurs, it is likely that direct detection using PCR or microscopy might again be valuable.

Use of concentration methods can improve the diagnostic sensitivity of these techniques [72,74,81]. Later in the clinical course, serology is the mainstay diagnostic option.

In terms of PCR/molecular diagnostics during acute stages of infection – and for assessment of non-human vertebrates or ticks –, real-time PCR assays for *B. miyamotoi* based upon either 16S rDNA [6] or the flagellin gene target have been described. The effectiveness of such assays for detection of the newly described *B. miyamotoi* variants nevertheless remains to be established [82]. Given the sympatric nature of *B. miyamotoi* and its closely related Lyme-associated borreliae, a logical strategy would be to utilise a multiplex assay able to screen for both pathogens simultaneously. A multiplex approach is also probably better suited to a diagnostic setting to avoid multistep methods and

reduce contamination risks that arise at each step. Some studies have suggested assays that differentiate conditions with overlapping clinical presenting features, such as *B. miyamotoi* infection and anaplasmosis [77] and have thus produced multiplex PCR assays to differentiate these infections [83].

Concerning serology, many studies have used the glycerophosphoryl diester phosphodiesterase (GlpQ) antigen expressed by members of the relapsing fever borreliae, but absent from *B. burgdorferi* s.l. [84]. Assays based upon GlpQ will not be *B. miyamotoi*-specific, but in areas where other members of the relapsing fever borreliae are not prevalent, such assays can be useful for population surveys and diagnosis on non-acute infections [85]. Besides the difficulties of GlpQ assays to distinguish *B. miyamotoi* from other relapsing fever borreliae, it is noteworthy that homologous proteins have been reported from both *Klebsiella pneumoniae* and *Salmonella enterica* [86]. In addition to lack of specificity, other reported limitations with the GlpQ antigen-based approach have been poor diagnostic sensitivity, with ability to only detect 28 of 36 convalescent samples from established cases [78].

As the use of vmps as antigens has also been explored for serodiagnosis [87], combinations of GlpQ together with mixtures of highly immunogenic vmps derived from *B. miyamotoi* have been evaluated as a way to improve the diagnostic efficacy [88]. This involved a comprehensive series of 182 PCR-confirmed Russian patients who were followed with sequential sera collected over several months post-infection. Notably, combinations of antigens provided superior sensitivity and/or specificity, with diagnostic titres for IgM, which were reached from 11 to 20 days post-disease onset and for IgG, from 21 to 50 days. This study used blood donor controls and additionally, controls with tick-borne encephalitis recruited from the same geographical region together with controls without tick exposure. Use of the combined antigens resulted in a sensitivity of 94.7% and specificity of 96.6% for IgM from 11 to 20 days post clinical presentation, thus providing important improvements over previous assays [88]. Assessment of duration of serological reactivity in seven of the 182 patients, showed that the IgM response waned within a year, while half (4/7) remained seropositive for IgG a year following disease. All individuals had been prescribed antimicrobial therapy.

On a cautionary note, the C6 ELISA used for diagnosing Lyme disease may additionally be positive in those infected by *B. miyamotoi* [69]. Furthermore, when using serological tests to detect *B. miyamotoi* in areas where multiple spirochaetes are endemic, the possibility of serological cross-reactivity between other relapsing fever borreliae such as *B. hermsii* should be kept in mind as this may obscure diagnosis [64,85].

Given the increasing recognition of co-infections among those with tick exposure, it might be prudent to take a

more holistic approach and screen for a broader range of tick-borne pathogens than just borreliae [89]. Some diagnostic centres have taken this approach, but many do not yet have the resources for more comprehensive tick-borne pathogen screening.

Isolation of borreliae is always a challenge as these microbes are particularly fastidious to cultivate, requiring complex liquid medium. Isolation is typically confirmed by dark field microscopy. The Barbour–Stoenner–Kelly (BSK) commercially-available medium (BSK-H) used for *B. burgdorferi* s.l. is unreliable for growth of relapsing fever spirochaetes (data not shown) and when used for *B. miyamotoi*, is unable to sustain passage of this organism [90]. Growth of *B. miyamotoi* has been achieved using modifications of Kelly–Pettenkofer medium (MKP) [16,91] or in a variation of BSK described as BSK-M [4]. Other studies have used media modifications with inclusion of 50% serum in order to cultivate these spirochaetes [92].

Propagation of isolates has additionally been achieved using inoculation of SCID mice. Typically, these will show spirochaetes in blood films between 7 and 14 days post-infection [34].

Treatment

Therapy for *B. miyamotoi* infection has typically followed guidelines used for treatment of Lyme borreliosis. Only a few cultivable strains have been recovered to date, restricting evaluation of different clinical management regimes. Moreover limited *in vitro* susceptibility testing has been undertaken to verify the efficacy of different therapeutic protocols [93]. Koetsveld and co-authors, noted resistance to amoxicillin *in vitro* (16–128 mg/L) using two isolates of *B. miyamotoi* [93]. Interestingly, this feature was also shared by the relapsing fever spirochaete *B. hermsii* that was assessed in parallel. Despite these *in vitro* findings, a patient treated with amoxicillin (and sultamicillin) responded without complications [80]. No treatment failures have been reported to date, thus it is probable that the hypothesised susceptibility profile being analogous to the Lyme-associated species is supported. Standard methods are not applicable for evaluation of the susceptibility testing of borreliae given their need for liquid cultivation, microaerophilic conditions and coupled with their slow mean generation time [94–96]. Akin to other members of the genus and spirochaetal infections in general, a proportion of patients may develop a Jarisch–Herxheimer reaction (JHR) associated with a sudden exacerbation of clinical signs upon onset of treatment [97]. Though reported, JHR does not appear frequently for cases of acute *B. miyamotoi* infection [2,74].

Future research directions

Much of the data so far arise from studies designed and funded to look either at tick-borne diseases or more specifically Lyme-associated borreliae. Though valuable, these studies might be biased and not reflect

TABLE 2

Global distribution of *Borrelia miyamotoi* clades and known vectors as at 2018

Tick species	Geographical range	Predominating <i>Borrelia miyamotoi</i> genotype (co-occurring variants)	Tick feeding preference	References
<i>Ixodes persulcatus</i>	Baltic to Far East	Asian	Generalist	[2,11]
<i>Ixodes pavlovskyi</i>	Western Siberia and Far East	Asian	Ground foraging birds, small mammals	[4,104]
<i>Ixodes ovatus</i>	South East Asia	Asian (new Asian variant)	Generalist	[4,10]
<i>Ixodes ricinus</i>	Northern Sweden to north Africa, Ireland to Ural in Russia	European (Asian)	Generalist	[11,15]
<i>Ixodes scapularis</i>	North-eastern and upper Midwestern United States	American	Generalist	[33,44,54]
<i>Ixodes pacificus</i>	Pacific coast of United States	American (new American variant)	Generalist	[44]
<i>Ixodes dentatus</i>	Eastern United States	American	Rabbits, hares Birds (larvae and nymphs)	[31]

some of the different ecological driving factors underpinning the observed epidemiology of this spirochaete. As such, we still need to more specifically address *B. miyamotoi* epidemiology further. This is important both for risk assessment and for application of control/intervention strategies. Indeed, many questions remain regarding our understanding of the pathobiology of this spirochaete (Table 3).

Future epidemiological studies need to consider the different genotypes of *B. miyamotoi*, particularly in areas of geographical overlap such as in Estonia and Russia [2,11]. Ability to assess the epidemiology of *B. miyamotoi* has been enhanced by the development of several multiplex PCR diagnostic methods providing a more cost-effective means for high throughput screening of samples [6,82,83]. These approaches, which are tailored to detect genotypes already described, however run the risk of missing hitherto undescribed variants.

Indeed, while three genotypes of *B. miyamotoi* (American, Asian and European) have been previously described, each associated with different tick vectors (Table 2) [3], recent studies have found more diversity within the *B. miyamotoi* species [10,12,28]. Future studies may shed light on how diverse *B. miyamotoi* genotype strains and variants behave. For example, it has not been comprehensively addressed if each of the *B. miyamotoi* genotypes or variants and their respective tick hosts are equally competent for transovarial transmission. Our knowledge to date is based upon studies that typically have only assessed one strain and tick species [33,54]. This information is currently extrapolated to others, but not underpinned by rigorous scientific enquiry.

Despite larger diversity recognised among *B. miyamotoi* strains, the species appears to be less heterogeneous than the *B. burgdorferi* s.l. complex, for which representatives sympatrically overlap with *B. miyamotoi*. Although it needs to be evaluated how strict new *B. miyamotoi* variants are to certain tick species, the variants identified to date have been found to be generally restricted to separate tick species, supporting the idea that, like for other *B. miyamotoi* spirochaetes, ticks still serve as both reservoirs and vectors for these [19]. Conversely, for the Lyme-associated species, ticks act mainly as vectors, while a plethora of vertebrates serve as reservoirs for horizontal infection, potentially driving diversity within this complex.

This being said, vertebrates also play a role in the ecology of *B. miyamotoi*. In this respect, it is notable that high infection rates were reported in turkeys [41]. Studies of avian vertebrates and their role in the ecology of *B. miyamotoi* have largely excluded ground foraging gallinaceous species, which is surprising given their established role as a reservoir for *B. burgdorferi* s.l. [98]. Looking into these avian species may provide missing pieces of the jigsaw of understanding the ecological niche of this spirochaete.

Coinfections by *B. burgdorferi* and *B. miyamotoi* have been observed in both vertebrates and ticks. Within ticks, a further level of complexity arises from the growing appreciation of how different microbes might facilitate survival or transmission. An ecological synergy is proposed whereby *B. burgdorferi* s.l. and *Babesia microti* benefit each other [99], but currently we have no knowledge of such interactions for *B. miyamotoi*. Importantly, we should consider how other pathogens present within ticks (including other *Borrelia*) will

TABLE 3

Unanswered questions regarding the pathobiology of *Borrelia miyamotoi*, 2018

What is the global epidemiological picture of <i>B. miyamotoi</i> infection?
Are the different spirochaetal variants restricted among certain tick species?
What is the ecology of this spirochaete?
What is the contribution of high incidence vertebrate species such as wild turkeys towards maintaining the ecological niche for this spirochaete?
What are the consequences of other pathogens present within ticks (including other <i>Borrelia</i>) upon the survival, persistence and transmissibility of <i>B. miyamotoi</i> ?
Do different strains show differential virulence within susceptible species?
What are the full range of clinical consequences within humans?
What are human risk factors for development of clinical disease above and beyond being immunocompromised?
Does blood transfusion present a substantive risk for infection?
What is the best diagnostic approach to take, using which sample types and at what time point during infection?
What is the best regime for therapeutic management of cases?

influence the survival, persistence and transmissibility of *B. miyamotoi*.

To anticipate human infection, consideration of the tick species likely to be encountered is important. An example might be the detected presence of *B. miyamotoi* within *I. dentatus* ticks that preferentially feed upon birds or lagomorphs and thus present a reduced risk of human infection [31]. Such information would enable instigation of risk prediction, modelling and targeted intervention approaches where justified.

Blood transfusion has been hypothesised as a risk factor for *B. miyamotoi* infection. Experimental studies have demonstrated the ability of *B. miyamotoi* to survive under conditions used for storage of blood transfusion products [100], raising concern that this could provide an additional source of infection (Table 3). Though theoretically possible, clinical cases presenting with acute signs, typically fever and associated non-specific influenza-like features, unlikely would present to donate blood [101]. Quantification of the numbers of spirochaetes present during human infection suggests that levels peak at ca 10^3 – 10^4 *B. miyamotoi* copies per mL during the second to third day of illness, then rapidly wane until day eight [22]. These authors suggested that PCR diagnosis was unreliable after the fourth day of clinical signs which would suggest low risk of transfusion related infection.

An enigma of our current understanding is why we fail to see a correlation between clinical cases of *B. miyamotoi* infection and tick infection prevalence. Human cases have occurred in some areas with relatively low tick infection prevalence, like Yekaterinburg, Russia, while in other countries or areas with higher prevalence in ticks, such as Mongolia or Hannover in Germany, no cases were reported. The reasons are likely to be multifactorial. Tick factors such as feeding preferences or the role of vertebrate hosts in intensifying or negatively impacting transmission could perhaps account for the observations. Another explanation might be

differential virulence in humans of the strains involved, as it remains to be solved if different strains/genotypes show differential virulence. Last, the absence of an evident relation between tick and human infection rates could also possibly result from lack of diagnostic ability, proximity to those with active research interest in tick-borne disease, or cases missed due to unspecific symptoms. The clinical features of *B. miyamotoi* indeed lack a diagnostic hallmark, and can potentially be misdiagnosed as granulocytic anaplasmosis [77,102]. Given these difficulties to recognise *B. miyamotoi* infections, it is likely that cases are under-reported. While spontaneous resolution of an infection with *B. miyamotoi* can occur without antimicrobial intervention [69,103], some clinical studies have noted severe infection, with considerable proportions of cases being hospitalised (24% [78]). Because when cases are diagnosed, they are likely to be promptly treated, the long-term consequences of human infection remain to be determined. While case studies of immunocompromised individuals report notable clinical features [64,72–74], the other risk factors that might influence the clinical progression towards disease are also not clear. Future detailed epidemiological studies of cases detected will enable a more complete clinical picture to unfold.

We also need to be aware of unusual presentations resulting from potential co-infection. The areas reporting cases are likely endemic for a variety of different tick-borne diseases. Clinically, presence of one tick-borne pathogen can obscure the concomitant presence of another. Consequently, it is a priority that those suspected of *B. miyamotoi* infection be also comprehensively screened for other tick-borne pathogens.

Diagnostic methods are nevertheless still widely considered ‘research tests’ and thus not generally available in more routine clinical settings. When these are possible, a delay in considering *B. miyamotoi* infection might further complicate their interpretation, due to the

poorly delineated clinical course of human infection. A further problem may be the variability of strains encountered which may affect diagnostic results.

Another problem relates to what the most appropriate diagnostic sample is. Ticks removed from patients have limited diagnostic value in that transmission may not have occurred and this might only be one of several ticks that might have bitten the individual in question. During acute infection, blood samples are a key sample to collect, however samples should be taken as early as possible and certainly before commencement of antimicrobial therapy. Collection of CSF is valuable in cases showing neurological features. This might require concentration of the specimen to improve diagnostic sensitivity [72,74]. Serum samples for serological investigation should be collected at all stages, with early sera used for assessment of seroconversion or increasing titre, and later samples for retrospective studies of prior exposure.

As for the therapeutic management of cases, a more comprehensive *in vitro* evaluation will be possible to guide this, once more isolates become available representing the diversity within this species.

Conclusion

Our understanding of *B. miyamotoi* and its ecology and infection potential have only recently started to unfold. The incidence of *B. miyamotoi* infection in humans is poorly explored, hampered by the lack of awareness and appropriate diagnostics. Our understanding of the clinical features of infection currently suggest a relatively mild infectious course without long-lasting sequelae for the majority of infected individuals, but with the caveat of being able to cause severe disease in the immunocompromised [72,74,86]. Current incidence is likely to be grossly under-reported, suggested by predicted tick bite exposure and tick prevalence data, as well as through the absence of a clinical presentation hallmark, making assessment of the impact of infection challenging.

Acknowledgements

We acknowledge ECDC for funding support through framework contract OJ/24/04/2014-PROC/2014/023.

Conflict of interest

None declared.

Authors' contributions

The initial review of the literature and compiling the review was undertaken by SJC and MVT. All authors (SC; MVT; AE-P; AP; AM & HZ) contributed towards the final preparation and review.

References

1. Fukunaga M, Takahashi Y, Tsuruta Y, Matsushita O, Ralph D, McClelland M, et al. Genetic and phenotypic analysis of *Borrelia miyamotoi* sp. nov., isolated from the ixodid tick *Ixodes persulcatus*, the vector for Lyme disease in Japan. *Int J Syst Bacteriol*. 1995;45(4):804-10. <https://doi.org/10.1099/00207713-45-4-804> PMID: 7547303
2. Platonov AE, Karan LS, Kolyasnikova NM, Makhneva NA, Toporkova MG, Maleev VV, et al. Humans infected with relapsing fever spirochete *Borrelia miyamotoi*, Russia. *Emerg Infect Dis*. 2011;17(10):1816-23. <https://doi.org/10.3201/eid1710.101474> PMID: 22000350
3. Crowder CD, Carolan HE, Rounds MA, Honig V, Mothes B, Haag H, et al. Prevalence of *Borrelia miyamotoi* in *Ixodes* ticks in Europe and the United States. *Emerg Infect Dis*. 2014;20(10):1678-82. <https://doi.org/10.3201/eid2010.131583> PMID: 25280366
4. Takano A, Toyomane K, Konnai S, Ohashi K, Nakao M, Ito T, et al. Tick surveillance for relapsing fever spirochete *Borrelia miyamotoi* in Hokkaido, Japan. *PLoS One*. 2014;9(8):e104532. <https://doi.org/10.1371/journal.pone.0104532> PMID: 25111141
5. Szekeres S, Lügner J, Fingerle V, Margos G, Földvári G. Prevalence of *Borrelia miyamotoi* and *Borrelia burgdorferi* sensu lato in questing ticks from a recreational coniferous forest of East Saxony, Germany. *Ticks Tick Borne Dis*. 2017;8(6):922-7. <https://doi.org/10.1016/j.ttbdis.2017.08.002> PMID: 28843481
6. Barbour AG, Bunikis J, Travinsky B, Hoen AG, Diuk-Wasser MA, Fish D, et al. Niche partitioning of *Borrelia burgdorferi* and *Borrelia miyamotoi* in the same tick vector and mammalian reservoir species. *Am J Trop Med Hyg*. 2009;81(6):1120-31. <https://doi.org/10.4269/ajtmh.2009.09-0208> PMID: 19996447
7. Ruyts SC, Frazer-Mendelewska E, Van Den Berge K, Verheyen K, Sprong H. Molecular detection of tick-borne pathogens *Borrelia afzelii*, *Borrelia miyamotoi* and *Anaplasma phagocytophilum* in Eurasian red squirrels (*Sciurus vulgaris*). *Eur J Wildl Res*. 2017;63(3):43. <https://doi.org/10.1007/s10344-017-1104-7>
8. Hamšíková Z, Coipan C, Mahríková L, Minichová L, Sprong H, Kazimírová M. *Borrelia miyamotoi* and co-infection with *Borrelia afzelii* in *Ixodes ricinus* Ticks and Rodents from Slovakia. *Microb Ecol*. 2017;73(4):1000-8. <https://doi.org/10.1007/s00248-016-0918-2> PMID: 27995301
9. Wagemakers A, Staarink PJ, Sprong H, Hovius JWR. *Borrelia miyamotoi*: a widespread tick-borne relapsing fever spirochete. *Trends Parasitol*. 2015;31(6):260-9. <https://doi.org/10.1016/j.pt.2015.03.008> PMID: 25892254
10. Iwabu-Itoh Y, Bazartseren B, Naranbaatar O, Yondonjamts E, Furuno K, Lee K, et al. Tick surveillance for *Borrelia miyamotoi* and phylogenetic analysis of isolates in Mongolia and Japan. *Ticks Tick Borne Dis*. 2017;8(6):850-7. <https://doi.org/10.1016/j.ttbdis.2017.06.011> PMID: 27668603
11. Geller J, Nazarova L, Katargina O, Järvekülg L, Fomenko N, Golovljova I. Detection and genetic characterization of relapsing fever spirochete *Borrelia miyamotoi* in Estonian ticks. *PLoS One*. 2012;7(12):e51914. <https://doi.org/10.1371/journal.pone.0051914> PMID: 23251652
12. Cook VJ, Fedorova N, Macdonald WP, Lane RS, Barbour AG. Unique strain of *Borrelia miyamotoi* in *Ixodes pacificus* ticks, California, USA. *Emerg Infect Dis*. 2016;22(12):2205-7. <https://doi.org/10.3201/eid2212.152046> PMID: 27479523
13. Jiang B-G, Jia N, Jiang J-F, Zheng Y-C, Chu Y-L, Jiang R-R, et al. *Borrelia miyamotoi* infections in humans and ticks, Northeastern China. *Emerg Infect Dis*. 2018;24(2):236-41. <https://doi.org/10.3201/eid2402.160378> PMID: 29350133
14. Dibernardo A, Cote T, Ogden NH, Lindsay LR. The prevalence of *Borrelia miyamotoi* infection, and co-infections with other *Borrelia* spp. in *Ixodes scapularis* ticks collected in Canada. *Parasit Vectors*. 2014;7(1):183. <https://doi.org/10.1186/1756-3305-7-183> PMID: 24731287
15. Wagemakers A, Jahfari S, de Wever B, Spanjaard L, Starink MV, de Vries HJC, et al. *Borrelia miyamotoi* in vectors and hosts in The Netherlands. *Ticks Tick Borne Dis*. 2017;8(3):370-4. <https://doi.org/10.1016/j.ttbdis.2016.12.012> PMID: 28065617
16. Koetsveld J, Kolyasnikova NM, Wagemakers A, Toporkova MG, Sarkisyan DS, Oei A, et al. Development and optimization of an *in vitro* cultivation protocol allows for isolation of *Borrelia miyamotoi* from patients with hard tick-borne relapsing fever. *Clin Microbiol Infect*. 2017;23(7):480-4. <https://doi.org/10.1016/j.cmi.2017.01.009> PMID: 28110053
17. Wilhelmsson P, Fryland L, Börjesson S, Nordgren J, Bergström S, Ernerudh J, et al. Prevalence and diversity of *Borrelia* species in ticks that have bitten humans in Sweden. *J Clin Microbiol*. 2010;48(11):4169-76. <https://doi.org/10.1128/JCM.01061-10> PMID: 20844223

18. Mun J, Eisen RJ, Eisen L, Lane RS. Detection of a *Borrelia miyamotoi* sensu lato relapsing-fever group spirochete from *Ixodes pacificus* in California. *J Med Entomol*. 2006;43(1):120-3. [https://doi.org/10.1603/0022-2585\(2006\)043\[0120:DOABM\]2.0.CO;2](https://doi.org/10.1603/0022-2585(2006)043[0120:DOABM]2.0.CO;2) PMID: 16506458
19. Lynn GE, Graham CB, Horiuchi K, Eisen L, Johnson TL, Lane RS, et al. Prevalence and geographic distribution of *Borrelia miyamotoi* in host-seeking *Ixodes pacificus* (Acari: Ixodidae) nymphs in Mendocino County, California. *J Med Entomol*. 2018;55(3):711-6. <https://doi.org/10.1093/jme/tjx258> PMID: 29365130
20. Blazejak K, Raulf M-K, Janeczek E, Jordan D, Fingerle V, Strube C. Shifts in *Borrelia burgdorferi* (s.l.) geno-species infections in *Ixodes ricinus* over a 10-year surveillance period in the city of Hanover (Germany) and *Borrelia miyamotoi*-specific Reverse Line Blot detection. *Parasit Vectors*. 2018;11(1):304. <https://doi.org/10.1186/s13071-018-2882-9> PMID: 29776377
21. Khasnatinov MA, Danchinova GA, Takano A, Kawabata H, Ohashi N, Masuzawa T. Prevalence of *Borrelia miyamotoi* in *Ixodes persulcatus* in Irkutsk City and its neighboring territories, Russia. *Ticks Tick Borne Dis*. 2016;7(2):394-7. <https://doi.org/10.1016/j.ttbdis.2015.12.016> PMID: 26750571
22. Karan L, Makenov M, Kolyasnikova N, Stukolova O, Toporkova M, Olenkova O. Dynamics of spirochetemia and early PCR Detection of *Borrelia miyamotoi*. *Emerg Infect Dis*. 2018;24(5):860-7. <https://doi.org/10.3201/eid2405.170829> PMID: 29664394
23. Adeolu M, Gupta RS. A phylogenomic and molecular marker based proposal for the division of the genus *Borrelia* into two genera: the emended genus *Borrelia* containing only the members of the relapsing fever *Borrelia*, and the genus *Borrelia* gen. nov. containing the members of the Lyme disease *Borrelia* (*Borrelia burgdorferi* sensu lato complex). *Antonie van Leeuwenhoek*. 2014;105(6):1049-72. <https://doi.org/10.1007/s10482-014-0164-x> PMID: 24744012
24. Margos G, Marosevic D, Cutler S, Derdakova M, Diuk-Wasser M, Emler S, et al. There is inadequate evidence to support the division of the genus *Borrelia*. *Int J Syst Evol Microbiol*. 2017;67(4):1081-4. <https://doi.org/10.1099/ijsem.0.001717> PMID: 27930271
25. Margos G, Gofton A, Wibberg D, Dangel A, Marosevic D, Loh S-M, et al. The genus *Borrelia* reloaded. *PLoS One*. 2018;13(12):e0208432. <https://doi.org/10.1371/journal.pone.0208432> PMID: 30586413
26. Mukhacheva TA, Salikhova II, Kovalev SY. Multilocus spacer analysis revealed highly homogeneous genetic background of Asian type of *Borrelia miyamotoi*. *Infect Genet Evol*. 2015;31:257-62. <https://doi.org/10.1016/j.meegid.2015.02.009> PMID: 25697887
27. Siński E, Welc-Faleciak R, Zajkowska J. *Borrelia miyamotoi*: A human tick-borne relapsing fever spirochete in Europe and its potential impact on public health. *Adv Med Sci*. 2016;61(2):255-60. <https://doi.org/10.1016/j.advms.2016.03.001> PMID: 27100337
28. Salkeld DJ, Nieto NC, Bonilla DL, Yoshimizu MH, Padgett KA. *Borrelia miyamotoi* infections in small mammals, California, USA. *Emerg Infect Dis*. 2018;24(12):2356-9. <https://doi.org/10.3201/eid2412.171632> PMID: 30457525
29. Marti Ras N, Lascola B, Postic D, Cutler SJ, Rodhain F, Baranton G, et al. Phylogenesis of relapsing fever *Borrelia* spp. *Int J Syst Bacteriol*. 1996;46(4):859-65. <https://doi.org/10.1099/00207713-46-4-859> PMID: 8863409
30. Vitorino LR, Margos G, Feil EJ, Collares-Pereira M, Zé-Zé L, Kurtenbach K. Fine-scale phylogeographic structure of *Borrelia lusitaniae* revealed by multilocus sequence typing. *PLoS One*. 2008;3(12):e4002. <https://doi.org/10.1371/journal.pone.0004002> PMID: 19104655
31. Hamer SA, Hickling GJ, Keith R, Sidge JL, Walker ED, Tsao JI. Associations of passerine birds, rabbits, and ticks with *Borrelia miyamotoi* and *Borrelia andersonii* in Michigan, U.S.A. *Parasit Vectors*. 2012;5(1):231. <https://doi.org/10.1186/1756-3305-5-231> PMID: 23057837
32. Yang Y, Yang Z, Kelly P, Li J, Ren Y, Wang C. *Borrelia miyamotoi* sensu lato in Père David Deer and *Haemaphysalis longicornis* Ticks. *Emerg Infect Dis*. 2018;24(5):928-31. <https://doi.org/10.3201/eid2405.171355> PMID: 29664385
33. Scoles GA, Papero M, Beati L, Fish D. A relapsing fever group spirochete transmitted by *Ixodes scapularis* ticks. *Vector Borne Zoonotic Dis*. 2001;1(1):21-34. <https://doi.org/10.1089/153036601750137624> PMID: 12653133
34. Lynn GE, Breuner NE, Eisen L, Hojgaard A, Replogle AJ, Eisen RJ. An immunocompromised mouse model to infect *Ixodes scapularis* ticks with the relapsing fever spirochete, *Borrelia miyamotoi*. *Ticks Tick Borne Dis*. 2019;10(2):352-9. <https://doi.org/10.1016/j.ttbdis.2018.11.017> PMID: 30503357
35. Fedorova N, Kleinjan JE, James D, Hui LT, Peeters H, Lane RS. Remarkable diversity of tick or mammalian-associated *Borrelia* in the metropolitan San Francisco Bay Area, California. *Ticks Tick Borne Dis*. 2014;5(6):951-61. <https://doi.org/10.1016/j.ttbdis.2014.07.015> PMID: 25129859
36. Szekeres S, Docters van Leeuwen A, Tóth E, Majoros G, Sprong H, Földvári G. Road-killed mammals provide insight into tick-borne bacterial pathogen communities within urban habitats. *Transbound Emerg Dis*. 2019;66(1):277-86. <https://doi.org/10.1111/tbed.13019> PMID: 30230270
37. Burri C, Schumann O, Schumann C, Gern L. Are *Apodemus* spp. mice and *Myodes glareolus* reservoirs for *Borrelia miyamotoi*, *Candidatus Neorhlichia mikurensis*, *Rickettsia helvetica*, *R. monacensis* and *Anaplasma phagocytophilum*? *Ticks Tick Borne Dis*. 2014;5(3):245-51. <https://doi.org/10.1016/j.ttbdis.2013.11.007> PMID: 24852511
38. Cosson J-F, Michelet L, Chotte J, Le Naour E, Cote M, Devillers E, et al. Genetic characterization of the human relapsing fever spirochete *Borrelia miyamotoi* in vectors and animal reservoirs of Lyme disease spirochetes in France. *Parasit Vectors*. 2014;7(1):233. <https://doi.org/10.1186/1756-3305-7-233> PMID: 24886071
39. Jahfari S, Ruyts SC, Frazer-Mendelewska E, Jaarsma R, Verheyen K, Sprong H. Melting pot of tick-borne zoonoses: the European hedgehog contributes to the maintenance of various tick-borne diseases in natural cycles urban and suburban areas. *Parasit Vectors*. 2017;10(1):134. <https://doi.org/10.1186/s13071-017-2065-0> PMID: 28270232
40. Heylen D, Fonville M, Docters van Leeuwen A, Stroo A, Duisterwinkel M, van Wieren S, et al. Pathogen communities of songbird-derived ticks in Europe's low countries. *Parasit Vectors*. 2017;10(1):497. <https://doi.org/10.1186/s13071-017-2423-y> PMID: 29047399
41. Scott MC, Rosen ME, Hamer SA, Baker E, Edwards H, Crowder C, et al. High-prevalence *Borrelia miyamotoi* infection among [corrected] wild turkeys (*Meleagris gallopavo*) in Tennessee. *J Med Entomol*. 2010;47(6):1238-42. <https://doi.org/10.1603/ME10075> PMID: 21175079
42. Wodecka B, Rymaszewska A, Skotarczak B. Host and pathogen DNA identification in blood meals of nymphal *Ixodes ricinus* ticks from forest parks and rural forests of Poland. *Exp Appl Acarol*. 2014;62(4):543-55. <https://doi.org/10.1007/s10493-013-9763-x> PMID: 24352572
43. Wodecka B, Skotarczak B. Identification of host blood-meal sources and *Borrelia* in field-collected *Ixodes ricinus* ticks in north-western Poland. *Ann Agric Environ Med*. 2016;23(1):59-63. <https://doi.org/10.5604/12321966.1196853> PMID: 27007518
44. Han S, Hickling GJ, Tsao JI. High prevalence of *Borrelia miyamotoi* among adult blacklegged ticks from white-tailed deer. *Emerg Infect Dis*. 2016;22(2):316-8. <https://doi.org/10.3201/eid2202.151218> PMID: 26811985
45. Kumagai Y, Sato K, Taylor KR, Zamoto-Niikura A, Imaoka K, Morikawa S, et al. A relapsing fever group *Borrelia* sp. is widely distributed among wild deer in Japan. *Ticks Tick Borne Dis*. 2018;9(3):465-70. <https://doi.org/10.1016/j.ttbdis.2017.12.016> PMID: 29329785
46. Furuno K, Lee K, Itoh Y, Suzuki K, Yonemitsu K, Kuwata R, et al. Epidemiological study of relapsing fever borreliae detected in *Haemaphysalis* ticks and wild animals in the western part of Japan. *PLoS One*. 2017;12(3):e0174727. <https://doi.org/10.1371/journal.pone.0174727> PMID: 28362864
47. Eisen RJ, Eisen L, Girard YA, Fedorova N, Mun J, Slikas B, et al. A spatially-explicit model of acarological risk of exposure to *Borrelia burgdorferi*-infected *Ixodes pacificus* nymphs in northwestern California based on woodland type, temperature, and water vapor. *Ticks Tick Borne Dis*. 2010;1(1):35-43. <https://doi.org/10.1016/j.ttbdis.2009.12.002> PMID: 20532183
48. Hamer SA, Hickling GJ, Walker ED, Tsao JI. Increased diversity of zoonotic pathogens and *Borrelia burgdorferi* strains in established versus incipient *Ixodes scapularis* populations across the Midwestern United States. *Infect Genet Evol*. 2014;27:531-42. <https://doi.org/10.1016/j.meegid.2014.06.003> PMID: 24953506
49. Wilhelmsson P, Lindblom P, Fryland L, Ernerudh J, Forsberg P, Lindgren P-E. Prevalence, diversity, and load of *Borrelia* species in ticks that have fed on humans in regions of Sweden and Åland Islands, Finland with different Lyme borreliosis incidences. *PLoS One*. 2013;8(11):e81433. <https://doi.org/10.1371/journal.pone.0081433> PMID: 24278437
50. Bunikis J, Barbour AG. Third *Borrelia* species in white-footed mice. *Emerg Infect Dis*. 2005;11(7):1150-1. <https://doi.org/10.3201/eid1107.041355> PMID: 16032795
51. Taylor KR, Takano A, Konnai S, Shimozuru M, Kawabata H, Tsubota T. *Borrelia miyamotoi* infections among wild rodents show age and month independence and correlation with *Ixodes persulcatus* larval attachment in Hokkaido, Japan. *Vector*

- Borne Zoonotic Dis. 2013;13(2):92-7. <https://doi.org/10.1089/vbz.2012.1027> PMID: 23210636
52. Telford SR 3rd, Goethert HK, Molloy PJ, Berardi VP, Chowdri HR, Gugliotta JL, et al. Borrelia miyamotoi disease: Neither Lyme disease nor relapsing fever. Clin Lab Med. 2015;35(4):867-82. <https://doi.org/10.1016/j.cll.2015.08.002> PMID: 26593262
53. van Duijvendijk G, Coipan C, Wagemakers A, Fonville M, Ersöz J, Oei A, et al. Larvae of Ixodes ricinus transmit Borrelia afzelii and B. miyamotoi to vertebrate hosts. Parasit Vectors. 2016;9(1):97. <https://doi.org/10.1186/s13071-016-1389-5> PMID: 26896940
54. Rollend L, Fish D, Childs JE. Transovarial transmission of Borrelia spirochetes by Ixodes scapularis: a summary of the literature and recent observations. Ticks Tick Borne Dis. 2013;4(1-2):46-51. <https://doi.org/10.1016/j.ttbdis.2012.06.008> PMID: 23238242
55. Richter D, Debski A, Hubalek Z, Matuschka F-R. Absence of Lyme disease spirochetes in larval Ixodes ricinus ticks. Vector Borne Zoonotic Dis. 2012;12(1):21-7. <https://doi.org/10.1089/vbz.2011.0668> PMID: 21923267
56. Breuner NE, Dolan MC, Replogle AJ, Sexton C, Hojgaard A, Boegler KA, et al. Transmission of Borrelia miyamotoi sensu lato relapsing fever group spirochetes in relation to duration of attachment by Ixodes scapularis nymphs. Ticks Tick Borne Dis. 2017;8(5):677-81. <https://doi.org/10.1016/j.ttbdis.2017.03.008> PMID: 28501504
57. Boyle WK, Wilder HK, Lawrence AM, Lopez JE. Transmission dynamics of Borrelia turicatae from the arthropod vector. PLoS Negl Trop Dis. 2014;8(4):e2767-2767. <https://doi.org/10.1371/journal.pntd.0002767> PMID: 24699275
58. Sarksyas DS, Platonov AE, Karan LS, Shipulin GA, Sprong H, Hovius JW. Probability of spirochete Borrelia miyamotoi transmission from ticks to humans. Emerg Infect Dis. 2015;21(12):2273-4. <https://doi.org/10.3201/eid2112.151097> PMID: 26584357
59. Hofhuis A, Herremans T, Notermans DW, Sprong H, Fonville M, van der Giessen JW, et al. A prospective study among patients presenting at the general practitioner with a tick bite or erythema migrans in The Netherlands. PLoS One. 2013;8(5):e64361. <https://doi.org/10.1371/journal.pone.0064361> PMID: 23696884
60. Hofhuis A, Harms M, van den Wijngaard C, Sprong H, van Pelt W. Continuing increase of tick bites and Lyme disease between 1994 and 2009. Ticks Tick Borne Dis. 2015;6(1):69-74. <https://doi.org/10.1016/j.ttbdis.2014.09.006> PMID: 25448421
61. Sarksyas DS, Maleev VV, Platonov AE, Platonova OV, Karan LS. [Relapsing (recurrent) disease caused by Borrelia miyamotoi]. Ter Arkh. 2015;87(11):18-25. <https://doi.org/10.17116/terarkh2015871118-25> PMID: 26821411
62. Krause PJ, Narasimhan S, Wormser GP, Barbour AG, Platonov AE, Brancato J, et al. Tick Borne Diseases Group. Borrelia miyamotoi sensu lato seroreactivity and seroprevalence in the northeastern United States. Emerg Infect Dis. 2014;20(7):1183-90. <https://doi.org/10.3201/eid2007.131587> PMID: 24960072
63. Krause PJ, Narasimhan S, Wormser GP, Rollend L, Fikrig E, Lepore T, et al. Human Borrelia miyamotoi infection in the United States. N Engl J Med. 2013;368(3):291-3. <https://doi.org/10.1056/NEJMc1215469> PMID: 23323920
64. Sato K, Sakakibara K, Masuzawa T, Ohnishi M, Kawabata H. Case control study: Serological evidence that Borrelia miyamotoi disease occurs nationwide in Japan. J Infect Chemother. 2018;24(10):828-33. <https://doi.org/10.1016/j.jiac.2018.06.017> PMID: 30057339
65. Barbour AG. Multiple and Diverse vsp and vlp Sequences in Borrelia miyamotoi, a hard tick-borne zoonotic pathogen. PLoS One. 2016;11(1):e0146283. <https://doi.org/10.1371/journal.pone.0146283> PMID: 26785134
66. Teegler A, Herzberger P, Margos G, Fingerle V, Kraiczky P. The relapsing fever spirochete Borrelia miyamotoi resists complement-mediated killing by human serum. Ticks Tick Borne Dis. 2014;5(6):898-901. <https://doi.org/10.1016/j.ttbdis.2014.07.011> PMID: 25104575
67. Stone BL, Brissette CA. Host immune evasion by Lyme and relapsing fever borreliae: Findings to lead future studies for Borrelia miyamotoi. Front Immunol. 2017;8:12. <https://doi.org/10.3389/fimmu.2017.00012> PMID: 28154563
68. Röttgerding F, Wagemakers A, Koetsveld J, Fingerle V, Kirschfink M, Hovius JW, et al. Immune evasion of Borrelia miyamotoi: CbiA, a novel outer surface protein exhibiting complement binding and inactivating properties. Sci Rep. 2017;7(1):303. <https://doi.org/10.1038/s41598-017-00412-4> PMID: 28331202
69. Sudhinda P, Wang G, Schriefer ME, McKenna D, Zhuge J, Krause PJ, et al. Insights into Borrelia miyamotoi infection from an untreated case demonstrating relapsing fever, monocytosis and a positive C6 Lyme serology. Diagn Microbiol Infect Dis. 2016;86(1):93-6. <https://doi.org/10.1016/j.diagmicrobio.2016.06.015> PMID: 27412815
70. Larsson C, Andersson M, Pelkonen J, Guo BP, Nordstrand A, Bergström S. Persistent brain infection and disease reactivation in relapsing fever borreliosis. Microbes Infect. 2006;8(8):2213-9. <https://doi.org/10.1016/j.micinf.2006.04.007> PMID: 16782384
71. Andersson M, Nordstrand A, Shamaei-Tousi A, Jansson A, Bergström S, Guo BP. In situ immune response in brain and kidney during early relapsing fever borreliosis. J Neuroimmunol. 2007;183(1-2):26-32. <https://doi.org/10.1016/j.jneuroim.2006.11.004> PMID: 17184846
72. Boden K, Lobenstein S, Hermann B, Margos G, Fingerle V. Borrelia miyamotoi-associated neuroborreliosis in immunocompromised person. Emerg Infect Dis. 2016;22(9):1617-20. <https://doi.org/10.3201/eid2209.152034> PMID: 27533748
73. Hovius JW, de Wever B, Sohne M, Brouwer MC, Coumou J, Wagemakers A, et al. A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet. 2013;382(9892):658. [https://doi.org/10.1016/S0140-6736\(13\)61644-X](https://doi.org/10.1016/S0140-6736(13)61644-X) PMID: 23953389
74. Gugliotta JL, Goethert HK, Berardi VP, Telford SR 3rd. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med. 2013;368(3):240-5. <https://doi.org/10.1056/NEJMoai209039> PMID: 23323900
75. Sato K, Takano A, Konnai S, Nakao M, Ito T, Koyama K, et al. Human infections with Borrelia miyamotoi, Japan. Emerg Infect Dis. 2014;20(8):1391-3. <https://doi.org/10.3201/eid2008.131761> PMID: 25061761
76. Jobe DA, Lovrich SD, Oldenburg DG, Kowalski TJ, Callister SM. Borrelia miyamotoi infection in patients from upper midwestern United States, 2014-2015. Emerg Infect Dis. 2016;22(8):1471-3. <https://doi.org/10.3201/eid2208.151878> PMID: 27434048
77. Chowdri HR, Gugliotta JL, Berardi VP, Goethert HK, Molloy PJ, Sterling SL, et al. Borrelia miyamotoi infection presenting as human granulocytic anaplasmosis: a case report. Ann Intern Med. 2013;159(1):21-7. <https://doi.org/10.7326/0003-4819-159-1-201307020-00005> PMID: 23817701
78. Molloy PJ, Telford SR 3rd, Chowdri HR, Lepore TJ, Gugliotta JL, Weeks KE, et al. Borrelia miyamotoi disease in the northeastern United States: a case series. Ann Intern Med. 2015;163(2):91-8. <https://doi.org/10.7326/M15-0333> PMID: 26053877
79. Krause PJ, Schwab J, Narasimhan S, Brancato J, Xu G, Rich SM. Hard tick relapsing fever caused by Borrelia miyamotoi in a Child. Pediatr Infect Dis J. 2016;35(12):1352-4. <https://doi.org/10.1097/INF.0000000000001330> PMID: 27626914
80. Yamano K, Ito T, Kiyonagi K, Yamazaki H, Sugawara M, Saito T, et al. Case report: Clinical features of a case of suspected Borrelia miyamotoi disease in Hokkaido, Japan. Am J Trop Med Hyg. 2017;97(1):84-7. <https://doi.org/10.4269/ajtmh.16-0699> PMID: 28719293
81. Larsson C, Bergström S. A novel and simple method for laboratory diagnosis of relapsing fever borreliosis. Open Microbiol J. 2008;2(1):10-2. <https://doi.org/10.2174/1874285800802010010> PMID: 19088905
82. Venczel R, Knoke L, Pavlovic M, Dzaferovic E, Vaculova T, Silaghi C, et al. A novel duplex real-time PCR permits simultaneous detection and differentiation of Borrelia miyamotoi and Borrelia burgdorferi sensu lato. Infection. 2016;44(1):47-55. <https://doi.org/10.1007/s15010-015-0820-8> PMID: 26168860
83. Wroblewski D, Gebhardt L, Prusinski MA, Meehan LJ, Halse TA, Musser KA. Detection of Borrelia miyamotoi and other tick-borne pathogens in human clinical specimens and Ixodes scapularis ticks in New York State, 2012-2015. Ticks Tick Borne Dis. 2017;8(3):407-11. <https://doi.org/10.1016/j.ttbdis.2017.01.004> PMID: 28131594
84. Schwan TG, Schrupf ME, Hinnebusch BJ, Anderson DE Jr, Konkel ME. GlpQ: an antigen for serological discrimination between relapsing fever and Lyme borreliosis. J Clin Microbiol. 1996;34(10):2483-92. PMID: 8880505
85. Krause PJ, Carroll M, Fedorova N, Brancato J, Dumouchel C, Akosa F, et al. Human Borrelia miyamotoi infection in California: Serodiagnosis is complicated by multiple endemic Borrelia species. PLoS One. 2018;13(2):e0191725. <https://doi.org/10.1371/journal.pone.0191725> PMID: 29420552
86. Krause PJ, Fish D, Narasimhan S, Barbour AG. Borrelia miyamotoi infection in nature and in humans. Clin Microbiol Infect. 2015;21(7):631-9. <https://doi.org/10.1016/j.cmi.2015.02.006> PMID: 25700888
87. Wagemakers A, Koetsveld J, Narasimhan S, Wickel M, Deponte K, Bleijlevens B, et al. Variable major proteins as targets for specific antibodies against Borrelia miyamotoi.

- J Immunol. 2016;196(10):4185-95. <https://doi.org/10.4049/jimmunol.1600014> PMID: 27076681
88. Koetsveld J, Kolyasnikova NM, Wagemakers A, Stukolova OA, Hoornstra D, Sarksyas DS, et al. Serodiagnosis of *Borrelia miyamotoi* disease by measuring antibodies against GlpQ and variable major proteins. Clin Microbiol Infect. 2018;24(12):1338.e1-7. <https://doi.org/10.1016/j.cmi.2018.03.009> PMID: 29550499
 89. Vayssier-Taussat M, Moutailler S, Michelet L, Devillers E, Bonnet S, Cheval J, et al. Next generation sequencing uncovers unexpected bacterial pathogens in ticks in western Europe. PLoS One. 2013;8(11):e81439. <https://doi.org/10.1371/journal.pone.0081439> PMID: 24312301
 90. Borgoyakov VV, Fomenko NV, Panov VV, Chikova ED. Infestation of taiga ticks with borrelias in the territory of Novosibirsk Scientific Center (Siberian Branch, Russian Academy of Sciences). Entomol Rev (Engl Transl). 2011;91(3):396-404. <https://doi.org/10.1134/S0013873811030158>
 91. Wagemakers A, Oei A, Fikrig MM, Miellet WR, Hovius JW. The relapsing fever spirochete *Borrelia miyamotoi* is cultivable in a modified Kelly-Pettenkofer medium, and is resistant to human complement. Parasit Vectors. 2014;7(1):418. <https://doi.org/10.1186/1756-3305-7-418> PMID: 25189195
 92. Margos G, Stockmeier S, Hizo-Teufel C, Hepner S, Fish D, Dautel H, et al. Long-term in vitro cultivation of *Borrelia miyamotoi*. Ticks Tick Borne Dis. 2015;6(2):181-4. <https://doi.org/10.1016/j.ttbdis.2014.12.001> PMID: 25561082
 93. Koetsveld J, Draga ROP, Wagemakers A, Manger A, Oei A, Visser CE, et al. In vitro susceptibility of the relapsing-fever spirochete *Borrelia miyamotoi* to antimicrobial agents. Antimicrob Agents Chemother. 2017;61(9):e00535-17. <https://doi.org/10.1128/AAC.00535-17> PMID: 28674060
 94. Ates L, Hanssen-Hübner C, Norris DE, Richter D, Krawczyk P, Hunfeld K-P. Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete *Borrelia burgdorferi*. Ticks Tick Borne Dis. 2010;1(1):30-4. <https://doi.org/10.1016/j.ttbdis.2009.11.004> PMID: 21771509
 95. Hunfeld K-P, Krawczyk P, Kekouk E, Schäfer V, Brade V. Standardised in vitro susceptibility testing of *Borrelia burgdorferi* against well-known and newly developed antimicrobial agents--possible implications for new therapeutic approaches to Lyme disease. Int J Med Microbiol. 2002;291(Suppl 33):125-37. [https://doi.org/10.1016/S1438-4221\(02\)80024-8](https://doi.org/10.1016/S1438-4221(02)80024-8) PMID: 12141737
 96. Hunfeld K-P, Ruzic-Sabljić E, Norris DE, Krawczyk P, Strle F. In vitro susceptibility testing of *Borrelia burgdorferi* sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother. 2005;49(4):1294-301. <https://doi.org/10.1128/AAC.49.4.1294-1301.2005> PMID: 15793100
 97. Butler T. The Jarisch-Herxheimer Reaction After Antibiotic Treatment of spirochetal infections: A review of recent cases and our understanding of pathogenesis. Am J Trop Med Hyg. 2017;96(1):46-52. <https://doi.org/10.4269/ajtmh.16-0434> PMID: 28077740
 98. Kurtenbach K, Peacey M, Rijpkema SGT, Hoodless AN, Nuttall PA, Randolph SE. Differential transmission of the genospecies of *Borrelia burgdorferi* sensu lato by game birds and small rodents in England. Appl Environ Microbiol. 1998;64(4):1169-74. PMID: 9546150
 99. Diuk-Wasser MA, Vannier E, Krause PJ. Coinfection by Ixodes tick-borne pathogens: Ecological, epidemiological, and clinical consequences. Trends Parasitol. 2016;32(1):30-42. <https://doi.org/10.1016/j.pt.2015.09.008> PMID: 26613664
 100. Thorp AM, Tonnetti L. Distribution and survival of *Borrelia miyamotoi* in human blood components. Transfusion. 2016;56(3):705-11. <https://doi.org/10.1111/trf.13398> PMID: 26689144
 101. Pavia CS, Plummer MM. Transfusion-associated Lyme disease - Although unlikely, it is still a concern worth considering. Front Microbiol. 2018;9:2070-2070. <https://doi.org/10.3389/fmicb.2018.02070> PMID: 30233543
 102. Jahfari S, Herremans T, Platonov AE, Kuiper H, Karan LS, Vasilieva O, et al. High seroprevalence of *Borrelia miyamotoi* antibodies in forestry workers and individuals suspected of human granulocytic anaplasmosis in the Netherlands. New Microbes New Infect. 2014;2(5):144-9. <https://doi.org/10.1002/nmi2.59> PMID: 25356364
 103. Hoornstra D, Koetsveld J, Sprong H, Platonov AE, Hovius JW. *Borrelia miyamotoi* disease in an immunocompetent patient, Western Europe. Emerg Infect Dis. 2018;24(9):1770-2. <https://doi.org/10.3201/eid2409.180806> PMID: 30124426
 104. Rar V, Livanova N, Tkachev S, Kaverina G, Tikunov A, Sabitova Y, et al. Detection and genetic characterization of a wide range of infectious agents in Ixodes pavlovskyi ticks in Western Siberia, Russia. Parasit Vectors. 2017;10(1):258. <https://doi.org/10.1186/s13071-017-2186-5> PMID: 28545549
 105. Mukhacheva TA, Kovalev SY. *Borrelia spirochetes* in Russia: Genospecies differentiation by real-time PCR. Ticks Tick Borne Dis. 2014;5(6):722-6. <https://doi.org/10.1016/j.ttbdis.2014.05.016> PMID: 25108777
 106. Cochez C, Heyman P, Heylen D, Fonville M, Hengeveld P, Takken W, et al. The presence of *Borrelia miyamotoi*, a relapsing fever spirochaete, in questing Ixodes ricinus in Belgium and in the Netherlands. Zoonoses Public Health. 2015;62(5):331-3. <https://doi.org/10.1111/zph.12154> PMID: 25212814
 107. Fonville M, Friesema IHM, Hengeveld PD, Docters van Leeuwen A, Jahfari S, Harms MG, et al. Human exposure to tickborne relapsing fever spirochete *Borrelia miyamotoi*, the Netherlands. Emerg Infect Dis. 2014;20(7):1244-5. <https://doi.org/10.3201/eid2007.131525> PMID: 24963562
 108. Padgett K, Bonilla D, Kjemtrup A, Vilcins I-M, Yoshimizu MH, Hui L, et al. Large scale spatial risk and comparative prevalence of *Borrelia miyamotoi* and *Borrelia burgdorferi* sensu lato in Ixodes pacificus. PLoS One. 2014;9(10):e110853. <https://doi.org/10.1371/journal.pone.0110853> PMID: 25333277

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2019.